These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19904281)

  • 1. Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.
    Harvey RD; Nettles J; Wang B; Sun SY; Lonial S
    Leukemia; 2009 Nov; 23(11):1939-40. PubMed ID: 19904281
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
    Zou W; Yue P; Lin N; He M; Zhou Z; Lonial S; Khuri FR; Wang B; Sun SY
    Clin Cancer Res; 2006 Jan; 12(1):273-80. PubMed ID: 16397052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
    Perrone G; Hideshima T; Ikeda H; Okawa Y; Calabrese E; Gorgun G; Santo L; Cirstea D; Raje N; Chauhan D; Baccarani M; Cavo M; Anderson KC
    Leukemia; 2009 Sep; 23(9):1679-86. PubMed ID: 19369963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Velcade and vitamin C: too much of a good thing?
    Catley L; Anderson KC
    Clin Cancer Res; 2006 Jan; 12(1):3-4. PubMed ID: 16397016
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of effective new treatments for multiple myeloma.
    Anderson KC; Pazdur R; Farrell AT
    J Clin Oncol; 2005 Oct; 23(28):7207-11. PubMed ID: 16145064
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib directly inhibits osteoclast function in multiple myeloma: implications into the management of myeloma bone disease.
    Terpos E
    Leuk Res; 2008 Nov; 32(11):1646-7. PubMed ID: 18614229
    [No Abstract]   [Full Text] [Related]  

  • 7. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
    Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
    [No Abstract]   [Full Text] [Related]  

  • 8. Bortezomib.
    Tariman JD; Lemoine C
    Clin J Oncol Nurs; 2003; 7(6):687-9. PubMed ID: 14705489
    [No Abstract]   [Full Text] [Related]  

  • 9. Captivating bortezomib: an active but still mysterious drug.
    Di Raimondo F; Conticello C
    Leuk Res; 2010 Apr; 34(4):411-2. PubMed ID: 19819547
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic use of tea derivatives: all that glitters is not gold.
    Mancuso C; Barone E
    Blood; 2009 Sep; 114(11):2359-60. PubMed ID: 19745081
    [No Abstract]   [Full Text] [Related]  

  • 11. Natural polyphenols antagonize the antimyeloma activity of proteasome inhibitor bortezomib by direct chemical interaction.
    Kim TY; Park J; Oh B; Min HJ; Jeong TS; Lee JH; Suh C; Cheong JW; Kim HJ; Yoon SS; Park SB; Lee DS;
    Br J Haematol; 2009 Aug; 146(3):270-81. PubMed ID: 19500098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 20S ways to apoptosis.
    McConkey DJ
    Nat Chem Biol; 2008 Sep; 4(9):528-9. PubMed ID: 18711380
    [No Abstract]   [Full Text] [Related]  

  • 13. Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.
    Nakano A; Abe M; Oda A; Amou H; Hiasa M; Nakamura S; Miki H; Harada T; Fujii S; Kagawa K; Takeuchi K; Watanabe T; Ozaki S; Matsumoto T
    Int J Hematol; 2011 Jun; 93(6):727-735. PubMed ID: 21526377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of new drugs for the treatment of patients with multiple myeloma.
    Kenealy M; Prince HM
    Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylseleninic acid antagonizes the cytotoxic effect of bortezomib in mantle cell lymphoma cell lines through modulation of Bcl-2 family proteins.
    Kassam S; Juliger S; Jia L; Joel SP
    Br J Haematol; 2012 Jan; 156(2):286-9. PubMed ID: 21910718
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment with bortezomib in multiple myeloma is associated with only a transient and brief increase of bone specific alkaline phosphatase.
    Haidl F; Plesner T; Lund T
    Leuk Res; 2012 Oct; 36(10):1296-9. PubMed ID: 22748823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple myeloma.
    Kyle RA; Rajkumar SV
    N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
    [No Abstract]   [Full Text] [Related]  

  • 20. [Situation of translational research and development of molecular-targeted agents for multiple myeloma].
    Kizaki M
    Nihon Rinsho; 2007 Dec; 65(12):2357-61. PubMed ID: 18069283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.